Clinical Trial: CRP On Radiobiological and Clinical Study On Virally-Induced Cancers Response to Radiotherapy

This study is not yet open for patient recruitment.

Sponsored by: International Atomic Energy Agency
Information provided by: International Atomic Energy Agency


To study clinical effects of two/four HDR brachytherapy applications and teletherapy with or without weekly Cisplatin in cervix cancer.
Condition Intervention Phase
Cervix Cancer
 Procedure: Radiotherapy alone and Radiotherapy with Cisplatin
Phase III

MedlinePlus related topics:  Cervical Cancer

Study Type: Interventional
Study Design: Treatment, Randomized, Open Label, Active Control, Parallel Assignment


Ages Eligible for Study:  18 Years and above,  Genders Eligible for Study:  Female

Inclusion Criteria:

  • Cervix Cancer

Exclusion Criteria:

  • unable to give an informed consent

Location and Contact Information

Please refer to this study by identifier  NCT00122772

Branislav Jeremic, M.D., Ph.D.      +43-1-2600  Ext. 21666

Study chairs or principal investigators

Branislav Jeremic, M.D., Ph.D.,  Study Director,  International Atomic Energy Agency (IAEA)   

More Information

Study ID Numbers:  E33024
Record last reviewed:  July 2005
Last Updated:  July 25, 2005
Record first received:  July 21, 2005 Identifier:  NCT00122772
Health Authority: United Nations: International Atomic Energy Agency processed this record on 2005-07-26


  • CRP (Lab Tests Online)

Common Treatments

[ Disclaimer: The information on GoldBamboo for any particular treatment, medicine, drug, or herbal product might be missing or incomplete, and should never be used as a single source of knowledge. GoldBamboo generally has links to authoritative sites displayed toward the bottom of each topic page under the heading "Resources". ]

Follow Us